China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Tesla Raises Cybertruck Prices by $5,000 in US 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Trump Buys SpaceX Shares After Record IPO 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Add as a preferred source on Google
BOSTON, May 01, 2018 -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that company management will present a corporate overview at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 4:10 p.m. ET in Boston.
A live webcast of the presentation can be accessed on the Investors section of resTORbio’s website at http://ir.restorbio.com/investors.
About resTORbio
resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program is targeting the selective inhibition of TORC1 - an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac and neurologic systems. RTB101, resTORbio’s lead drug candidate, is a selective, orally administered, TORC1 inhibitor currently being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. The company expects to develop RTB101 for additional aging-related indications such as heart failure or neurodegenerative diseases.
Contacts:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Michael Lampe
Scient PR
484-575-5040
[email protected]
